RxDoctor Payments Data

William Wilmer, MD

Nephrology · Westerville, OHNPI 1750380481

Payments from drug & device makers

$379in general payments, 2019–2025

Across 31 payments — averaging $12.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calliditas Therapeutics US Inc.$128
  • Travere Therapeutics, Inc.$48
  • Aurinia Pharma U.S., Inc.$39
  • AMAG Pharmaceuticals, Inc.$33
  • Fresenius USA Marketing, Inc.$31
  • Amgen$31
  • plus $69 from 4 others

What the payments were for

  • Food & beverage$30179%
  • Education$7821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$379 in reported general payments places this provider in the 25th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$156,823
Medicare patients
336
Services billed
1,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide15$62,236
AuryxiaFerric Citrate19$40,579
JardianceEmpagliflozin15$20,518
Cinacalcet Hcl44$18,237
MounjaroTirzepatide15$16,359
Sevelamer Carbonate58$9,457
Eplerenone40$6,347
Spironolactone-HctzSpironolact/Hydrochlorothiazid170$5,205
LokelmaSodium Zirconium Cyclosilicate11$4,626
Calcitriol245$3,677
Amiloride Hcl94$3,192
Torsemide105$3,049
Nifedipine ErNifedipine89$2,718
Spironolactone217$2,514
Doxazosin Mesylate83$2,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$31$62,23615 claims
Akebia Therapeutics IncAuryxia$17$40,57919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 450 nephrology providers in Ohio.

Other nephrology in Westerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →